Delhi HC restrains generic pharma firms from making, selling patent drug of Novartis

The plea said the plaintiff through a press release of January 28, 2019 issued by the defendant came to know about its act in launching a pharmaceutical composition comprising of the patented combination of Sacubitril and Valsartan tablet under the brand VALSAC as a combination drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3w8cGcS
via IFTTT